PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

2021341 citationsJournal Articlehybrid Open Access

Authors

PRODIGY showed that neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, is effective and tolerable in Korean patients with LAGC.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 39, Issue 26, pp. 2903-2913

Field-Weighted Citation Impact: 34.25